Stock EFTR EFFECTOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Chart eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Delayed Nasdaq
Other stock markets
 12:57:02 2024-06-03 pm EDT 		5-day change 1st Jan Change
1.55 USD -3.12% Intraday chart for eFFECTOR Therapeutics, Inc. -10.86% -86.65%
May. 20 EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer CI
May. 09 EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
b5e91a0b46a7425283.UUD8ZJngh5CgpDMFaDCwnYc2khkGiBMQYwhpihl3mQg.JivLBf3Z9unZ6klwMgXm7vNbwldn0EdBLl4zxHRFoUcldrgq2IH_qOLuUA~5e7bc0cfd6bfc3307c19a29af61311f8
  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. Charts eFFECTOR Therapeutics, Inc.
  5. News Chart